HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more
HansBiomed Corporation (042520) - Net Assets
Latest net assets as of September 2025: ₩33.89 Billion KRW
Based on the latest financial reports, HansBiomed Corporation (042520) has net assets worth ₩33.89 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩126.41 Billion) and total liabilities (₩92.52 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩33.89 Billion |
| % of Total Assets | 26.81% |
| Annual Growth Rate | 2.68% |
| 5-Year Change | -23.77% |
| 10-Year Change | -27.62% |
| Growth Volatility | 24.87 |
HansBiomed Corporation - Net Assets Trend (2012–2025)
This chart illustrates how HansBiomed Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HansBiomed Corporation (2012–2025)
The table below shows the annual net assets of HansBiomed Corporation from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | ₩33.89 Billion | -49.52% |
| 2024-09-30 | ₩67.12 Billion | +34.38% |
| 2023-09-30 | ₩49.95 Billion | +9.46% |
| 2022-09-30 | ₩45.63 Billion | +2.66% |
| 2021-09-30 | ₩44.45 Billion | -26.33% |
| 2020-09-30 | ₩60.34 Billion | -28.23% |
| 2019-09-30 | ₩84.07 Billion | +28.74% |
| 2018-09-30 | ₩65.30 Billion | +21.54% |
| 2017-09-30 | ₩53.73 Billion | +14.76% |
| 2016-09-30 | ₩46.82 Billion | +8.48% |
| 2015-09-30 | ₩43.16 Billion | +9.57% |
| 2014-09-30 | ₩39.39 Billion | +34.39% |
| 2013-09-30 | ₩29.31 Billion | +21.93% |
| 2012-09-30 | ₩24.04 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to HansBiomed Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4632317198000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩80.03 Billion | 237.44% |
| Total Equity | ₩33.70 Billion | 100.00% |
HansBiomed Corporation Competitors by Market Cap
The table below lists competitors of HansBiomed Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MOIL Limited
NSE:MOIL
|
$246.60 Million |
|
Grab Holdings Limited Warrant
NASDAQ:GRABW
|
$246.68 Million |
|
Hwaway Tech Corp Ltd
SHE:001380
|
$246.71 Million |
|
PRIMIS FINANCIAL DL-01
F:7H80
|
$246.73 Million |
|
TomTom N.V
PINK:TMOAF
|
$246.41 Million |
|
Golden Friends
TWO:4506
|
$246.40 Million |
|
Skytech Inc.
TW:6937
|
$246.22 Million |
|
FD Technologies Plc
PINK:FDRVF
|
$246.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HansBiomed Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 66,874,048,790 to 33,703,812,120, a change of -33,170,236,670 (-49.6%).
- Net loss of 31,341,350,190 reduced equity.
- Other factors decreased equity by 1,828,886,480.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-31.34 Billion | -92.99% |
| Other Changes | ₩-1.83 Billion | -5.43% |
| Total Change | ₩- | -49.60% |
Book Value vs Market Value Analysis
This analysis compares HansBiomed Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.94x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 8.84x to 16.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-09-30 | ₩4971.46 | ₩43950.00 | x |
| 2017-09-30 | ₩5705.36 | ₩43950.00 | x |
| 2018-09-30 | ₩6651.25 | ₩43950.00 | x |
| 2019-09-30 | ₩7592.23 | ₩43950.00 | x |
| 2020-09-30 | ₩6026.47 | ₩43950.00 | x |
| 2021-09-30 | ₩4439.82 | ₩43950.00 | x |
| 2022-09-30 | ₩4732.02 | ₩43950.00 | x |
| 2023-09-30 | ₩4243.81 | ₩43950.00 | x |
| 2024-09-30 | ₩5149.32 | ₩43950.00 | x |
| 2025-09-30 | ₩2595.20 | ₩43950.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HansBiomed Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -92.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -34.91%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 3.75x
- Recent ROE (-92.99%) is below the historical average (-8.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 10.48% | 14.33% | 0.65x | 1.13x | ₩114.52 Million |
| 2013 | 11.72% | 17.11% | 0.60x | 1.14x | ₩503.04 Million |
| 2014 | 8.88% | 16.63% | 0.47x | 1.13x | ₩-441.46 Million |
| 2015 | 11.38% | 20.96% | 0.45x | 1.21x | ₩593.61 Million |
| 2016 | 9.88% | 15.92% | 0.45x | 1.38x | ₩-56.66 Million |
| 2017 | 14.57% | 20.04% | 0.49x | 1.49x | ₩2.46 Billion |
| 2018 | 6.15% | 7.76% | 0.56x | 1.41x | ₩-2.51 Billion |
| 2019 | 13.29% | 14.85% | 0.50x | 1.79x | ₩2.46 Billion |
| 2020 | -29.57% | -22.27% | 0.61x | 2.18x | ₩-23.87 Billion |
| 2021 | -41.14% | -30.95% | 0.46x | 2.91x | ₩-22.73 Billion |
| 2022 | 13.47% | 8.26% | 0.57x | 2.89x | ₩1.58 Billion |
| 2023 | -46.91% | -29.53% | 0.64x | 2.49x | ₩-27.96 Billion |
| 2024 | -10.80% | -8.90% | 0.67x | 1.82x | ₩-13.91 Billion |
| 2025 | -92.99% | -34.91% | 0.71x | 3.75x | ₩-34.71 Billion |
Industry Comparison
This section compares HansBiomed Corporation's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $104,450,906,167
- Average return on equity (ROE) among peers: 6.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HansBiomed Corporation (042520) | ₩33.89 Billion | 10.48% | 2.73x | $246.58 Million |
| Shinhung (004080) | $87.31 Billion | 3.50% | 0.52x | $10.80 Million |
| Osang Healthcare Co.,Ltd (036220) | $199.86 Billion | 20.34% | 0.25x | $37.44 Million |
| JVM Co. Ltd (054950) | $98.83 Billion | 10.23% | 0.72x | $117.37 Million |
| Huvitz Co. Ltd (065510) | $51.68 Billion | 16.97% | 0.32x | $43.64 Million |
| Vieworks Co. Ltd (100120) | $188.04 Billion | 17.80% | 0.28x | $101.54 Million |
| Corentec Co Ltd (104540) | $48.30 Billion | -3.04% | 0.46x | $40.80 Million |
| Hironic Co. Ltd (149980) | $40.72 Billion | 7.13% | 0.15x | $23.71 Million |
| Laseroptek Co., Ltd. (199550) | $-3.94 Billion | 0.00% | 0.00x | $21.68 Million |
| Humasis Co. Ltd (205470) | $229.26 Billion | -13.28% | 0.45x | $48.97 Million |